DSIP vs Melatonin: Sleep Research Compared

What is the difference between DSIP and melatonin?

DSIP is a small research peptide studied for sleep effects, while melatonin is a hormone your own body produces to time sleep and wake.

DSIP, short for delta sleep-inducing peptide, is a nine-amino-acid peptide first isolated from research on sleep signaling. Its name comes from early observations tied to delta-wave (deep) sleep. Human data on DSIP is small in size and mixed in outcome (Schneider-Helmert et al., 1981, PMID 6895513; Bes et al., 1992, PMID 1299794).

Melatonin is a hormone secreted by the pineal gland, mainly at night. It acts as a timing signal, telling the body that darkness has arrived. Its role in the circadian system is described in detail across the research literature (NIH MedlinePlus; Zisapel, 2018). Because it is a hormone, its biology is understood in far more detail than DSIP's.

The short version: melatonin is an established circadian hormone with a deep evidence base, and DSIP is an experimental peptide with limited, contested support.

How does each one work?

Melatonin binds receptors that shift circadian timing; DSIP's mechanism in humans is still unresolved.

Melatonin acts on MT1 and MT2 receptors in the brain that help set the body's internal clock. Rising melatonin at night is one of the signals that aligns sleep timing with the dark period (Zisapel, 2018). This receptor-based, circadian role is why melatonin is studied most for sleep timing rather than as a sedative.

DSIP's mechanism is less defined. Early researchers proposed it promoted slow-wave sleep and modulated stress-related signaling, but the pathway in humans was never pinned down with the confidence melatonin's has been (Graf and Kastin, 1984). Reviewers have described DSIP as an unresolved case, with biological activity reported across many systems but no single agreed mechanism (Kovalzon and Strekalova, 2006). Human data on DSIP remains limited.

One reason effects are hard to characterize is pharmacokinetics. DSIP is a simple linear peptide with no disulfide bonds, and it is rapidly broken down in body fluids by aminopeptidases, which is consistent with a plasma half-life measured in minutes (Nyberg et al., 1990). Precise human half-life figures are sparse and vary between reports, so this should be read as short rather than exact.

What does the research actually report for DSIP?

A small early study reported that median total sleep time rose about 59 percent, but the metric was narrow and the finding was not confirmed in a later double-blind trial.

In one of the most cited early reports, six healthy volunteers received a slow intravenous DSIP infusion at 25 nmol/kg in a double-blind cross-over design, and median total sleep time increased by about 59 percent within a 130-minute window after treatment compared with placebo (Schneider-Helmert et al., 1981, PMID 6895513). Two points matter for reading that number. First, the 59 percent figure describes median total sleep time inside a short post-infusion window, not a general night-long gain and not a responder rate. Second, the sample was six people, so the estimate is fragile.

A separate report in six middle-aged chronic insomniacs described longer sleep duration and fewer interruptions, but the sleep-promoting effect appeared only in the second hour after injection, with a slight arousing effect in the first hour (Schneider-Helmert et al., 1981, PMID 7028502). A later placebo-controlled, double-blind study in chronic insomniac patients found higher sleep efficiency and shorter sleep latency on some objective measures, but no change on most others, including patients' own quality ratings, and the authors concluded that short-term DSIP was unlikely to be of major therapeutic benefit (Bes et al., 1992, PMID 1299794).

Reading the DSIP evidence: the human literature is small, dated, and contested. Sample sizes were tiny, designs varied, and the strongest early signal was not replicated with the same magnitude. Treat any DSIP claim as preliminary, not settled.

What does the research report for melatonin?

Melatonin is one of the most studied compounds in circadian science, with a documented role in signaling sleep timing.

Unlike DSIP, melatonin has a broad, replicated research base describing its circadian function and its use in studies of sleep timing and shift-related sleep disruption (Zisapel, 2018; Tordjman et al., 2017). A meta-analysis of controlled human trials in normal sleepers and people with primary insomnia found a statistically significant reduction in sleep onset latency after immediate-release melatonin, although it did not improve other aspects of sleep quantity (Zisapel, 2018). The evidence gap between the two compounds is the central point of this comparison: melatonin is characterized and replicated, DSIP is not.

DSIP vs melatonin: decision table

The table below summarizes what published sources report. It is not dosing guidance. Ranges below reflect what research described, not a recommendation.

Which has better evidence, DSIP or melatonin?

Melatonin has substantially stronger and more reproducible evidence than DSIP.

Melatonin's circadian role is documented across a wide, consistent body of work, including receptor pharmacology and pooled trial data on sleep onset (Zisapel, 2018; Tordjman et al., 2017). DSIP rests on a small number of early studies, and the strongest early signal, a roughly 59 percent rise in median total sleep time over a 130-minute window, came from six subjects and was not confirmed at the same magnitude later (Schneider-Helmert et al., 1981, PMID 6895513; Bes et al., 1992, PMID 1299794). On evidence quality alone, melatonin is the far more characterized option.

What are the cautions?

Neither compound is a treatment, and DSIP in particular lacks the safety and efficacy data that would support any confident conclusion.

For DSIP, the main caution is uncertainty: human data is limited, old, and not reproduced at scale, so effects and safety are not well established (Bes et al., 1992, PMID 1299794). For melatonin, effects are better described, but it is a hormone with real biological activity, and timing matters, which is a clinical question rather than a self-directed one (Zisapel, 2018).

Anyone considering either for research or personal use should route decisions on suitability, timing, and dose to a qualified clinician. This page reports what studies found; it does not tell you what to take.